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Abstract
Background: To compare the biological characteristics of three types of human hepatocellular carcinoma multi-
drug resistant cell sub-lines Bel-7402/ADM models established by three methods.
Methods: Established human hepatocellular carcinoma adriamycin (ADM) multi-drug resistant cell sub-lines models
Bel-7402/ADMV, Bel-7402/ADML and Bel-7402/ADMS by three methods of in vitro concentration gradient increased
induction, nude mice liver-implanted induction and subcutaneous-implanted induction respectively. Phase contrast
microscopy was used to observe the cells and the MTT (methyl thiazolyl tetrazolium) method was used to detect
drug resistance of the three different sub-lines of cells.
Results: The three groups of drug resistant cells, Bel-7402/ADMV, Bel-7402/ADML and Bel-7402/ADMS generated
cross-resistance to ADM and CDDP (cis-Diaminedichloroplatinum), but showed a significant difference in resistance
to Bel-7402 IC50 value (P < 0.01). The doubling times were significantly extended compared to the parent cell line
(39 h) and were 65 h (Bel-7402/ADMV), 46 h (Bel-7402/ADML), and 45 h (Bel-7402/ADMS). The excretion rates of
ADM were significantly increased compared with the parent cell (34.14%) line and were 81.06% (Bel-7402/ADMV),
66.56% (Bel-7402/ADML) and 61.56% (Bel-7402/ADMS). Expression of P-gp and MRP in the three groups of resistant
cells was significantly enhanced (P < 0.01). There was no significant variation in the expression of GSH/GST (P >
0.05).
Conclusions: Stable resistance was involved in the resistant cell line model established by the above three
methods. Liver implantation was a good simulation of human hepatocellular and proved to be an ideal model
with characteristics similar to human hepatocellular biology and the pharmacokinetics of anticancer drugs.
Background
The current treatment of hepatocellular carcinoma,
especially hepatocellular carcinoma in middle and
advanced stages, is a comprehensive therapy using a
combination of surgery and chemotherapy. Chemother-
apy plays a critical role in the treatment of hepatocellu-
lar carcinoma. Nevertheless, multi-drug resistance
(MDR) [1,2] of hepatocellular carcinoma cells to multi-
ple chemotherapeutics renders chemotherapy for hepa-
toma insufficient. Therefore, the target of drug
resistance and its reverse strategy is one of the hotspots
of hepatocellular carcinoma research.
Establishing a reliable tumor MDR model is the foun-
dation for the study of tumor MDR and its reversal. In
this study, we established three different human hepato-
cellular carcinoma drug-resistance cell sub-lines of Bel-
7402/ADM by applying ADM by three normal methods.
We compared the biological characteristics the three
cell sub-lines to acquire a comparatively ideal drug-
resistance model which paved the way for revealing the
clinical multidrug resistance phenomenon and the
screening of a reversal agent.
Materials and methods
Cells and Animals
Human hepatocellular carcinoma cell line Bel-7402
was purchased from Shanghai Institute of Biological
Products. Four-week-old BALB/c-nu/nu nude mice
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any medium, provided the original work is properly cited.weighting 12-16 g were purchased from Shanghai
Shilaike Co., Ltd., and were bred in the specific patho-
gen free (SPF)Animal Center, School of Life Science,
University of Science and Technology of China.
Establishment of a multi-drug resistance cell model based
on nude mice liver implantation and subcutaneous
implantation
A total of 20 male nude mice aged 4-6 weeks were used.
Ten mice were anesthesized by an intraperitoneal injec-
tion with chloral hydrate (430 mg/kg). A transverse inci-
sion was performed under the xiphoid process. A 0.2-ml
Bel-7402 cell suspension (density equal to 1 × 10
8/ml)
was injected into the parenchyma of the right hepatic
lobe and the abdomen was closed. The ten mice were
randomly divided into the liver implantation experimen-
tal group or the control group with equal members (n =
5 for each group). Another 10 animals were subcuta-
neously injected with 0.2-ml Bel-7402 cell suspension
(density equal to 1 × 10
8/ml) into the right anterior
axilla. they were also randomly divided into experimen-
t a la n dc o n t r o lg r o u p s( n=5f o re a c hg r o u p ) .A l la n i -
mals were bred in SPF condition. On the third day,
nude mice in the experimental groups underwent an
intraperitoneal injection with ADM at a dose of 1.5 mg/
kg each week for 8 weeks. Mice in the control groups
underwent an intraperitoneal injection with an equal
volume of normal saline solution. Skin reaction, appetite
and psychological status were recorded according to the
observation in each day. The tumor volume was calcu-
lated by the following formula: V = πab
2/a (“a” repre-
sents the long diameter of the tumor, “b” represents the
short diameter of the tumor). When the experiment was
completed, the nude mice were sacrificed, the tumor
was obtained and levigated in asepsis. A 0.25% trypsin
solution was used to digest the cells for 2-3 min and to
produce a mono-cell suspension. Cells were inoculated
in a 25-ml sterile culture flask for primary culture. After
multiple passages and purification, the hepatocellular
implantation drug-resistant cell sub-lines Bel-7402/
ADML (liver-implanted induction) and the subcutaneous
implantation drug-resistant cell sub-lines Bel-7402/
ADMS (subcutaneous-implanted induction) were
obtained. Tumor tissue was fixed with 1% osmium tetr-
oxide, embedded in resin, and cut into ultra thin sec-
tions. After uranyl acetate and citric acid double
staining, the sections were observed by an transmission
electron microscope (Zeiss 902).
Establishment of a multi-drug resistance model by in
vitro induction
The ADM concentration gradient progressive increase
induction method was applied. Bel-7402 cells at a
concentration of 5 × 10
5/ml in the logarithmic phase
were inoculated in a 25-ml culture flask and cultured
for 24 h. The culture solution was replaced with an
ADM culture solution at a low concentration (0.01 μg/
ml). After the 24-h culture, the solution containing
drugs was discarded. Cells were digested with 0.25%
trypsin and centrifuged at 1000 rpm for 3 min. The
cells were collected and re-inoculated in a 25-ml culture
flask containing a solution without ADM at a concentra-
tion of 1 × 10
5/ml. While cell growth was in the loga-
rithmic phase, drug concentration was elevated and the
extent of improvement increased the cell survival rate
60-70%. This protocol was repeated for a period of
approximately 6 months, until the cells exhibited stable
growth and proliferation in a culture medium with 0.5
μg/ml ADM. This cell sub-lines named Bel-7402/ADMV
(vitro induction).
Detection of cellular sensitivity to drug by MTT (methyl
thiazolyl tetrazolium) methods
Four groups of cells (the parent cell line and the three
different groups of drug-resistant cell sub-lines) in the
logarithmic phase of growth were obtained for the pre-
paration of cell suspension. Cell concentration was
adjusted to 5 × 10
5/ml and 200 μl (approximately 10
5
cells) was placed in each well of a 96-well culture plate.
After a 24-h culture, the following investigational drugs
were added: ADM, CDDP, MMC, MTX and 5-FU. In
accordance with peak blood concentrations of a clinical
dose of each drug, the concentration range was varied
from 10
3-t o1 0
-3-fold of peak blood concentrations.
Seven diverse experimental concentrations were defined
as follows: 10
3,1 0
2,1 0
1,1 0
0,1 0
-1,1 0
-2 and 10
-3 fold of
peak blood concentration. A control group without
drugs was also set and included five different duplicate
wells in each experimental concentration. All cells were
cultured at 37°C and 5% CO2 for 24 h. Twenty microli-
ters of an MTT (5 mg/ml) solution was added to each
well and cells were cultured for an additional 4 h.
Supernatants were discarded after termination of the
culture and 150 μl of dimethyl sulphoxide (DMSO) was
added to each well. Plates were shaken for 10 min and a
microplate reader was used to measure the optical den-
sity (OD) value at a wavelength of 570 nm (the correc-
tion wavelength was 630 nm) to calculate cell survival
rate. The following equation was used to calculate cell
survival rate: cell survival rate = (the OD value in each
experiment well/the OD value in the control well)
×100%. The 50% of inhibition concentration (IC50)o f
drug was measured by chartography. The resistance
index (RI) = the IC50 of drug-resistant cells/the IC50 of
parent cell line. MTT experiments were repeated three
times on different days.
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doubling time
Four groups of cells with an excellent growth condition
were obtained and RPMI- 1640 complete culture solu-
tion was applied to prepare a cell suspension (5 × 10
3/
ml) of each. A 6-well plate (1 ml/well) was inoculated.
Cell counting was performed after 1, 2, 3, 4, 5, 6, or 7 d
of inoculation, when 3 pores were obtained for each day
and mean values were obtained. The culture time was
set as the X-axis and cell numbers were set as the
Y-axis to draw the growth curve. According to the Pat-
terson equation, cell doubling time was calculated as fol-
lows: Td = tlg2/lg (Nt/N0) where Td: doubling time (h);
t: required time when cell numbers increased from N0
to Nt; N0: cell numbers in the inoculation; Nt: cell
numbers after culture for t hours.
Uptake and excretion of ADM
Flow cytometry was used to measure fluorescence inten-
sity of ADM and to reflect its concentration indirectly.
Four groups of cells in the logarithmic phase of growth
were obtained to prepare a cell suspension of 1 × 10
6/
ml cells. ADM was added to a final concentration of 4.0
μg/ml. Cells were placed in a CO2 incubator for 20 min,
and then a 1-ml solution was obtained for centrifuga-
t i o n .C o l dP B Sw a su s e dt ow a s ht h ec e l l st w i c ea n d
they were resuspended in 0.5 ml PBS. The relative fluor-
escent intensity of ADM was detected by flow cytometry
immediately (excitation wavelength was 479 nm, emis-
sion wavelength was 587 nm). In the excretion experi-
ment, the above cells were centrifuged, washed in cold
RPMI-1640 culture solution, re-suspended in culture
solution without adding drug and placed in a CO2 incu-
bator for 60 min. After this incubation period, cells
were centrifuged, washed with PBS and the relative
fluorescence intensity of ADM was detected by flow
cytometry. The excretion rate of ADM reflected the
excretive function of ADM by cells. The excretion rate
of ADM = 100% × (uptake value - stagnation value)/
uptake value. Experiments were repeated 5 times at dif-
ferent time points.
Measurements of P-glycoprotein (P-gp), multidrug
resistance-associated protein (MRP) and the expression of
glutathione S-transfer enzyme system (GSH/GST) detected
by flow cytometry
The four groups of drug-resistant cells and parent cells
in the logarithmic phase of growth (1 × 10
8/ml) were
obtained with five tubes in each group. PBS (4°C, 0.01
mol/l, pH 7.4) was applied twice then MRK16(MDR1),
MRPrl (MRP) and GSH/GST mouse-anti-human mono-
clonal antibody were added for 1 h at 4°C. The mouse-
anti-human isotype-matched monoclonal antibody was
applied as a control Goat-anti-mouse fluorescent labeled
IgG was added, incubated at 4°C for 30 min, and fluor-
escence intensity was detected by flow cytometry.
Statistical analysis
All data are expressed as the mean ± SD and analyses
were carried out using SPSS10.0 software (SPSS Inc,
Chicago, IL). The Student’s t-test and one-way ANOVA
were used for comparisons among the means. A p-value
less than 0.05 was considered statistically significant.
Results
Drug-resistant model of subcutaneous and liver
implantation tumors
The subcutaneous implanted tumors were all success-
fully inoculated (10/10). The mean incubation periods in
the experimental group and the control group were 18
± 6 d. The growth of tumors in the experimental group
was 3.60 ± 0.58 mm
3/day, whereas in the control group,
it was 3.75 ± 0.26 mm
3/ d a y .T h e1 0n u d em i c ew i t h
liver implanted tumors were all successfully inoculated.
The growth of tumors in the experimental group was
3.50 ± 0.37 mm
3/day, whereas in the control group, it
was 3.70 ± 0.41 mm
3/day. During the 8-wks breeding
and induction of ADM, tumors in each group grew well,
with ruddy skin. In the liver implanted group, 2 mice
developed abdominal dropsy, but no cachexia or death
occurred. After 8 wks, all nude mice were sacrificed.
The general morphology of the implanted tumor in
both the experimental and control groups showed no
significant difference. Tumors assumed an ellipse or
irregular sublobe morphology. Under electron micro-
scope, the tumor cells share many similarities with
human hepatocellular carcinoma cells, including
enlarged nuclei, hyperchromatic nucleoli, and multiple
nuclear membrane incisures (Figure 1). The mean
tumor weight was 1.48 ± 0.21 g. Fibrous tissue abun-
dantly surrounded the tumor. The incisal surface of the
tumor body was gray. The minority of tumors showed a
scattered and clustered distribution. In addition, three
mice exhibited metastases in the abdominal cavity in the
liver implanted group.
Observation of cell morphology
Under a phase contrast microscope, Bel-7402 cells were
fusiform, aligned and compact with well-distributed
sizes, distinct boundaries and growth with adherence.
After the addition of drugs, the majority of cells
appeared apoptotic and subsequently dissolved. The size
of the surviving cells was unequal, the cellular profile
was unclear and adherence was reduced. After about
two weeks, cell growth recovered and the above varia-
tions in the acute stage had disappeared. The morphol-
ogy of resistant-cells was irregular, with slightly
augmented volume, which signifies accumulated growth.
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plasm and the nucleus exhibited slight shrinkage.
Sensitivity of the three types of cell sub-lines toward
anticancer drugs (Table 1)
Table 1 indicates that the three resistant cell sub-lines
generated cross-resistance toward ADM and CDDP but
showed no cross-resistance to mitomycin (MMC), meth-
otrexate (MTX), 5 -fluorouracid (5- FU).
Growth curve and doubling time (Figure 2)
The doubling time of drug-resistant cells was signifi-
cantly extended compared with parent cells. The dou-
bling times in Bel-7402, Bel-7402/ADMS, Bel-7402/
ADML and Bel-7402/ADMV cells were 39 h, 45 h, 46 h
and 65 h, respectively.
Uptake and excretion of ADM (Table 2)
The excretion rate of Bel-7402, Bel-7402/ADMS,B e l -
7402/ADML and Bel-7402/ADMV cells to ADM were
34.14%, 61.56%, 66.56% and 81.06%, respectively. The
relative fluorescent intensity in each group of cells was
reduced after the excretion of ADM and drug-resistant
cells were more obvious compared with parent cells.
Variation of expression of P-gp, MRP and GSH/GST
detected by flow cytometry (Table 3)
Expression of P-gp in the three groups of the resistant
cells was significantly enhanced (P <0 . 0 1 ) .T h eM R P
fluorescence staining rates were also significantly raised in
the three groups of drug resistant cells, the in vitro induc-
tion group with the highest rate, the other two groups
relatively lower. It is shown that the peak dramatically
moves to the right of the coordinate system (Figure 3).
The expression of GSH/GST in the three groups showed
no statistical significance by paired-comparison (P >0.05).
Discussion
Current condition and progression of hepatoma
therapeutics
Hepatic cell carcinoma is generally accepted as one of
the most harmful malignant tumors, with high
Figure 1 Under electron microscope, the tumor cells share
many similarities with human hepatocellular carcinoma cells,
including enlarged nuclei, hyperchromatic nucleoli, and
multiple nuclear membrane incisures. (×10000).
Table 1 Sensitivity of Bel-7402/ADMS, Bel-7402/ADML and Bel-7402/ADMV cells to multiple chemotherapy drugs
Drug IC50 (mg.L
-1,x ¯±s)R I
Bel-7402 Bel-7402/ADMS Bel-7402/ADML Bel-7402/ADMV RIS RIL RIV
ADM 2.09 ± 0.13 26.69 ± 0.46 26.92 ± 0.38 46.93 ± 0.82 12.77 12.88 22.45
CDDP 0.98 ± 0.11 12.92 ± 3.45 13.46 ± 3.00 25.18 ± 3.57 13.18 13.73 25.69
MMC 0.54 ± 0.05 0.57 ± 0.08 0.60 ± 0.08 0.62 ± 0.04 1.06 1.11 1.15
MTX 0.15 ± 0.05 0.17 ± 0.05 0.20 ± 0.06 0.21 ± 0.05 1.13 1.33 1.4
5-FU 119.65 ± 6.46 120.78 ± 4.84 121.60 ± 6.15 123.66 ± 5.00 1.01 1.02 1.03
Note: By least significant difference (LSD) paired-comparison in both ADM and CDDP groups, except Bel-7402/ADML vs. Bel-7402/ADMS (P > 0.05), there is no
statistical significance. In other groups of resistant cells, there is a significant difference by paired-comparison. In addition, in MMC, MTX and 5-FU groups, there is
no statistical significance by paired-comparison (P > 0.05).
Figure 2 Cells growth curve. The doubling time of the cells was
proportional to the drug-resistance of cell lines.
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n e s s e da nu p r i s i n gi nt h ei n c i d e n c er a t eo fh e p a t o m a .
Therefore, it is of vital importance to improve the thera-
peutic treatment of hepatoma. Excision is still the best
alternative in the multiple therapeutic methods for the
treatment of hepatoma [3,4]. Nevertheless, the diagnos-
tic rate in earlier hepatoma is quite low and the progres-
sion of disease is comparatively rapid. Therefore, the
majority of patients have lost a surgical opportunity
after final diagnosis. References indicate that 60% of
patients have clinical or endoscopic metastasis in the
final diagnosis of hepatoma [5]. Thus, non-operative
therapy showed better practical value than operative
therapy. Chemotherapy is also commonly used in non-
operative methods, and is a kind of general therapeutic
method for the treatment of the primary tumors, metas-
tases and inferior clinical metastatic tumors. However,
the involvement of MDR seriously affects the che-
motherapeutic effect in hepatoma.
Significance of the establishment of multi-drug resistant
human hepatocellular carcinoma cell sub-lines model
The chemotherapeutic effect was restricted due to the
involvement of multi-drug resistance of hepatocellular
carcinoma cells. The related MDR of hepatoma and its
clinical reversal is becoming a critical clinical problem
that needs a further solution. Research on this aspect
requires the establishment of a reliable multi-drug resis-
tant cell model [6].
Currently, the establishment of a multi-drug resistant
human hepatocellular carcinoma cell line model
includes methods such as the application of an in vitro
culture to induce tumor MDR, multi-drug resistant gene
transfection and the induction of drug-resistance by
nude mice implanted model. Induction of tumor MDR
in vitro culture also required two types of methods, the
drug concentration incremental gradient method and
the high-concentration intermittent drug-induced
method [7,8]. The drug-resistance method induced by
nude mouse in vivo transplantation includes three meth-
ods: subcutaneous implantation, liver implantation and
abdominal implantation. There are advantages and dis-
advantaged involved in the various methods. In vitro
drug concentration incremental gradient induction, liver
and subcutaneous implanted induction of nude mice are
commonly used as three methods for establishing multi-
drug resistant human ADM hepatocellular carcinoma
cell sub-lines. The tumor cell microenvironment
includes various factors such as temperatures, pH
values, local oxygen concentration, cell matrix, nutri-
tional condition and medications, which play a critical
regulatory role in the biological behavior of cells and
MDR expression. Therefore, further clarification on
methods that can establish drug-resistant cell models
that accurately reflect the practical process of clinical
drug-resistance are needed. Our experiment aimed to
identify which drug-resistant cell line is the ideal model
for the study of the mechanism of hepatoma drug-resis-
tance and paves a way for the further investigation of
drug-resistant and its reversal.
Comparisons of three drug-resistance models
The induction of multi-drug resistance in tumor cells
was caused by factors such as P-gp [9], MRP, LRP, GST,
glutathione, glutathione S-transferase, protein kinase C,
apoptosis-related gene (bcl-2, c-myc, p53), and the high-
expression of GCS in the cancer cell living environment
and variation of DNA type II topoisomerase activity
Table 2 Cellular relative fluorescent intensity after the uptake and excretion of ADM
Cell Cellular relative fluorescence intensity of ADM Excretion rate of ADM (%)
After Uptake After Excretion
Bel-7402 (Parent) 11.19 ± 0.23 7.37 ± 0.16 34.14
Bel-7402/ADMS 15.27 ± 0.22 5.87 ± 0.13 61.56
Bel-7402/ADML 15.61 ± 0.18 5.22 ± 0.13 66.56
Bel-7402/ADMV 19.11 ± 0.15 3.62 ± 0.17 81.06
F 1338.016 531.312
P 0.000 0.000
Note: By LSD paired-comparison after the uptake and excretion, drug-resistant cellular relative fluorescent intensity of ADM showed significant differences (P <
0.05).
Table 3 Staining rate of P-gp, MRP and GSH/GST
fluorescent cells analyzed by flow cytometry
Cell Expression rate (%, x¯ ± s)
P-gp MRP GSH/GST
Bel-7402 (Parent) 19.59 ± 0.62 21.29 ± 1.14 26.92 ± 1.79
Bel-7402/ADMS 65.92 ± 1.41 56.88 ± 1.49 27.76 ± 1.00
Bel-7402/ADML 68.10 ± 1.88 58.84 ± 2.35 28.97 ± 1.42
Bel-7402/ADMV 91.93 ± 2.49 78.28 ± 1.23 27.57 ± 1.24
F 1512.300 1064.757 1.890
P 0.000 0.000 0.172
Notes: By LSD paired-comparison in both P-gp and MRP groups, except for
Bel-7402/ADML vs. Bel-7402/ADMS (P > 0.05), there was no statistical
significance. In other groups of resistant cells, there was a significant
difference by paired-comparison (P < 0.01). In addition, for GSH/GST, there
was no statistical significance by paired-comparison (P > 0.05).
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quite complicated, the drug-resistant phenotype of MDR
cells was contained in cell specificity, distinct inductive
medicines and diverse induction methods, the concluded
drug-resistant phenotype was not quite uniform [18-20].
In our experiment, we compared three types of multi-
drug resistant human hepatocellular carcinoma cell sub-
lines ADM model established by three methods. The
summary is shown below.
Comparisons of biological characteristics in the three
models
The morphology of each drug-resistant cell line was
irregular, volume was slightly increased compared with
the parental generation, growth velocity was slower
which enables accumulative growth, cell boundaries
were obscure, massive particles and vacuoles were
observed in the cytoplasm, and a slight shrinkage of the
nucleus appeared. The in vitro induction of drug-resis-
tant cells showed significant differences and the
morphology of drug-resistant cell induced by in vivo
implantation was close to the parental generation.
The doubling times of the three drug-resistant cell
lines, which were significantly extended compared with
the parent cell line, revealed that growth velocity and
the reproductive activity of the drug-resistant cell line
applied by an in vitro concentration gradient incremen-
tal method was significantly lower than that of the other
two kinds of in vivo inductions.
For the mechanisms of drug-resistance, the higher
increase of drug excretion induced by a drug efflux
pump was one of the most common drug-resistant reac-
tions [21]. For this reason, we detected and compared
the influx and efflux of ADM in three kinds of cells.
The results indicated that the efflux rates of the four
groups were 34.14%, 61.56%, 66.56% and 81.06%. Efflux
rate of ADM by the resistant cell was significantly
increased which was reflected as the drug stagnation
diminished. This caused the intracellular drug concen-
tration to decrease and diminish the impairment of cell
Figure 3 The flow cytometry histograms of MRP expression. With the MRP fluorescence staining rate increased gradually in the four groups,
the peak dramatically moves to the right of the coordinate system.
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main cause of the higher drug-resistant index.
Expressions of P-gp and MRP in the three groups of
drug-resistant cells were significantly increased com-
pared with the parental generation. The expression of
GSH/GST in the three groups showed no statistical sig-
nificance by paired comparison (P >0 . 0 5 ) .O u rr e s u l t s
suggested that the high expression of P-gp might induce
the decrease of intracellular ADM accumulation and
constitute a molecular basis of drug resistance. More-
over, MRP over-expression might be another molecular
basis of drug resistance. Nevertheless, there was no sig-
nificant relationship between the formation of drug
resistance of hepatoma carcinoma cell and the expres-
sion of GSH/GST.
Advantages and disadvantages of in vitro induction and
in vivo induction
Our study proved that the superiority of a drug-resistant
cell model established by the in vitro concentration gra-
dient incremental method is that the drug-resistant
index and stability were high. The disadvantage was that
cell proliferation was quite low. The induction of the
drug-resistance process wasted much time and it was
easier to induce contaminants during the induction. The
superiority of the drug-resistance model established by
nude mice in vivo inductionw a sd u et oi t ss t r o n g e r
reproductive activity, short time of induction (generally
about 8 weeks) and the low possibility of contamination.
However, the disadvantages mainly included the inferior
drug resistance and stability.
In conclusion, we considered the drug resistance
model established by the two kinds of methods based
on nude mice in vivo introduction was comparatively
ideal. Firstly, stable drug resistance was involved in both
methods. Secondly, both methods reflected the forma-
tion of clinical drug resistance accurately. Both of the
modeling methods and medications during chemother-
apy were quite similar; large doses of chemotherapeutics
were injected into the living body in a short time and
reached a certain blood drug level to kill the cancer
cells. Clinically, large doses and short-range administra-
tions [22] are commonly used to relieve the side effect
of chemotherapeutics and to improve the therapeutic
effect. Similar to the clinical drug-resistant cells, all cells
had quite strong reproductive activity. Patients with
multi-drug resistance have recurrence or metastasis of
primary tumors [23] which indicates that the drug-resis-
tant cells appearing clinically show quite strong prolif-
erative and metastatic ability. Tumor cell groups
selected by the effects of drugs had stronger survival
superiority and were able to overcome the inhibition of
chemotherapy to keep normal growth and proliferation.
The short time of the induction, lower possibility of
contamination and the relatively simple operation are
also its merits.
Comparison of the two in vivo induction methods
We compared the two drug-resistance models with nude
mice in vivo implantation progressively. Our results vali-
dated that aspects such as cell morphology, multiples of
drug resistance, the influx and efflux of drug and the
variation of P-gp, MRP and GSH/GST were all funda-
mentally similar. The advantages of subcutaneous
implantation were due to its simple operation and easy
observation. However, the tumor growth environment
was different from human hepatoma; the tumor growth
was relatively local and generated limited distant metas-
tases. The superiority of liver implantation was quite
obvious, especially in tumor growth environment, loca-
tion and biological behavior were quite similar to
human hepatoma, the proportion of the genesis of
tumor metastasis, infiltration and ascites were quite
high. Therefore, the drug-resistance model established
by nude mice liver implantation was capable of better
simulating human hepatoma. The ideal model has simi-
lar characteristics of human heptoma biology and the
pharmacokinetics of anti-cancer drugs. The utilization
of this model not only allows the exploration of the
molecular mechanism of hepatoma multi-drug resis-
tance with multiple angles and targets, but also provided
an ideal experiment using plates for the screening of
hepatoma drug-resistant reversal agents.
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